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Abstract 
Blood lipids are important modifiable risk factors for coronary heart disease and drugs 
target different lipid fractions. Considerable efforts have been made to identify genetic variants 
that modulate responses to drugs in the hope of optimizing their use. Pharmacogenomics and 
new biotechnologies now allow for meaningful integration of human genetic findings and 
therapeutic development for increased efficiency and precision of lipid-lowering drugs. 
Polygenic predictors of disease risk are also changing how patient populations can be stratified, 
enabling targeted therapeutic interventions to patients more likely to derive the highest 
benefit, marking a shift from single variant to genomic approaches in pharmacogenomics. 
Introduction 
Coronary artery disease (CAD) is a major cause of mortality and morbidity in 
industrialized countries with a growing global prevalence [1]. Even though the etiology of CAD is 
multifactorial, blood lipids are important modifiable risk factors and different lipid fractions 
have been identified as independent risk factors for CAD [2-4]. Notably, the traditional blood 
lipids (LDL-c, HDL-c and triglycerides) as well as other lipoproteins like lipoprotein(a) [Lp(a)] all 
contribute to CAD risk and multiple current and future drugs aim at modulating them. 
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Genomic approaches have provided a most valuable tool to help unravel the complexity 
of blood lipid regulation. Both family-based rare variant studies and large-scale genome-wide 
scans have contributed to the identification of more than 250 loci confidently associated with 
lipid phenotypes [5-11]. These findings have helped guide and interpret functional studies 
which elucidated multiple pathways for lipid regulation that informed the design of modern 
lipid-modifying agents. 
In this review, we will take the broad definition of pharmacogenomics including the use 
of genetic variation to better understand drugs and, in the more classical sense, the inter-
individual variation in drug response. We will discuss how genetic associations and Mendelian 
randomization studies can help predict the safety and efficacy of drug targets and how genetic 
variants can affect drug response and be used as predictive biomarkers. Finally, we will consider 
a recent shift from approaches based on single variants to methods focusing on polygenic risk 
which can offer useful prognostic biomarkers informing clinical treatment decisions in targeted 
populations. 
Current approaches for lipid regulation 
Statins 
In 1994, the Scandinavian Simvastatin Survival Study (4S) marked a turning point in the 
management of CAD by demonstrating a 42% risk reduction in coronary death for individuals 
treated with simvastatin over a 5.4 years median follow-up [12,13]. Since then, the use of 
statins has grown to an estimated prevalence of 17% in 2011-2012 in the United States in a 
nationally representative sample of the National Health and Nutrition Examination Survey 
(NHANES) [14]. Statins inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) 
reductase responsible for a rate-limiting step of cholesterol biosynthesis in the mevalonate 
pathway [15]. Despite possible pleiotropic effects, the primary benefit of statins is achieved 
through their LDL lowering effect [16,17]. 
The genetic determinants of statin response are amongst the most widely studied 
subjects in cardiovascular pharmacogenomics. A 2015 systematic review identified 8 GWAS of 
statin response and 166 candidate gene studies [18]. Among the confidently associated genes 
are transporters (SLCO1B1, ABCG2), metabolizing enzymes (CYP2D6, CYP3A4, CYP7A1), 
lipoprotein or metabolism genes (APOE, LDLR, COQ2) and the drug target itself (HMGCR) [18-
20]. Variants in these genes have been associated with both the LDL-c response to statins and 
the development of adverse effects such as statin-induced myopathy. For instance, the ABCG2 
gene encodes the ATP-binding cassette subfamily G member 2, a multidrug transporter 
contributing to the intestinal absorption and the hepatic elimination of multiple statins [21]. In 
rosuvastatin users, a common SNP in this gene (rs2231142) was associated with increased LDL-c 
reduction of 6.9% which is equivalent to the effect of doubling the dose of the drug [22]. 
Despite their positive risk-benefit ratio, statins are associated with an increased risk of 
muscle-related adverse reactions ranging from non-specific myalgias to rhabdomyolisis [23]. 
These symptoms can lead to statin discontinuation and consequently to an increased risk of 
coronary events which prompted research efforts aimed at identifying genetic predictors of 
statin-induced myopathy [24]. Genetic studies have been hampered by small sample sizes and 
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heterogeneous diagnostic criteria for statin-induced myopathy for which definitions range from 
reversible on-statin muscle pain to 10 times the upper limit of normal levels for creatine kinase 
(CK), a biomarker of muscle damage. Additionally, in a recently published unblinded and 
unrandomized extension of the Anglo-Scandinavian Cardiac Outcomes Trial, the rate of 
adjudicated muscle-related adverse effects was reported to be increased in unblinded statin 
users compared to blinded users suggesting a nocebo effect [25]. This effect, compounded by 
the relatively small sample size of genetic studies of statin induced myopathy, could explain the 
limited success and reproducibility of these approaches. Nonetheless, a gene has been 
consistently associated with statin-induced myopathy in genetic studies, SLCO1B1, encoding the 
organic anion transporting polypeptide 1B1 responsible for hepatic statin uptake [26]. Clinical 
guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIP) suggest 
avoiding simvastatin for individuals with low SLCO1B1 function based on haplotypes containing 
the loss-of-function rs4149056T>C mutation [27]. One promising venue to further improve our 
understanding of statin-induced myopathy is to gain a better knowledge of disease biomarkers 
to achieve more sensitive diagnoses. Reference CK ranges are notoriously wide and predicting 
an individual’s normal values using genomic data could lead to improved detection of statin-
induced myopathy. Our group has conducted a GWAS of CK levels and identified variants in two 
possibly relevant genes, CKM and LILRB5 but the derivation of a diagnostic biomarker based on 
these findings remains ongoing work [28]. 
Multiple high-quality reviews provide a more thorough description of the genetic 
determinants of statin response and here we will focus on recent developments and other lipid-
regulating drugs [20,29]. The latest large-scale effort to identify genetic determinants of statin 
response was a meta-analysis of GWAS including over 40,000 individuals. This study confirmed 
previously known associations with APOE and LPA while identifying SLCO1B1 and SORT1 as 
novel determinants of the baseline adjusted LDL-c response to statins. The SORT1 gene encodes 
sortilin 1 which is responsible for LDL receptor (LDLR)-independent uptake of apoB-containing 
lipoproteins including LDL [30]. The identified variants are predicted to increase SORT1 
expression depleting LDL subtypes with increased SORT1 affinity in favor of subtypes with 
greater LDLR affinity. This relative enrichment then favors statin response as statins increase 
the activity of the SREBP2 transcription factor leading to increased LDLR expression [31]. 
Ezetimibe 
Another commonly used drug to lower LDL-c levels is ezetimibe, which blocks the 
Niemann-Pick C1-like protein 1 (encoded by the NPC1L1 gene) intestinal transporter of dietary 
sterols. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) 
comparing ezetimibe to placebo on a background of simvastatin therapy showed a HR = 0.94 
and an absolute risk reduction in cardiovascular outcomes of 2% in acute coronary syndrome 
patients, with a difference in LDL-c medians between both arms of 15.8 mg/dl [32]. Few 
pharmacogenomic studies of ezetimibe have been conducted, but polymorphisms in the 
SLCO1B1 (also known as OATP1B1) gene could modulate ezetimibe excretion and drug 
response [33]. Variants in the drug target itself (NPC1L1) have also been associated with 
improved reduction in LDL-c levels in patients treated with ezetimibe [34]. 
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For both statins and ezetimibe, genetic variants in the genes encoding their drug targets 
have effects concordant with those of the drugs. In a 2x2 Mendelian randomization study, 
Ference et al. used variants in the drug targets to derive gene-based scores predictive of 
protein activity to predict the effect of statin monotherapy (HMGCR mutations), ezetimibe 
monotherapy (NPC1L1 mutations) or ezetimibe+statin (mutations in both genes) on CAD risk 
[35]. Individuals with NPC1L1 mutations but no HMGCR mutation, when compared to the 
control group, had lower LDL-c levels by 2.4 mg/dl and a reduced risk for CAD of 5%. Individuals 
with HMGCR mutations and no NPC1L1 mutations had almost identical effects. Interestingly, in 
the group of individuals carrying mutations in both genes, the LDL-c reduction was of 5.8 mg/dl 
and the risk reduction for CAD was of nearly 11%. This finding is in line with the IMPROVE-IT 
trial results showing the added benefit of further reducing LDL-c levels using ezetimibe in 
addition to statins [32]. 
Fibrates 
Fibrates are agonists of the peroxisome proliferator-activated receptor alpha (PPARα) 
that reduce triglyceride levels and total cholesterol and increase HDL-c levels [36]. In a large 
meta-analysis of randomized controlled trials, fibrate therapy was associated with a 10% risk 
reduction of major cardiovascular events [37]. The results from the ACCORDION trial, a post-
trial follow-up of The Action to Control Cardiovascular Risk in Diabetes study group (ACCORD), 
found that diabetic patients with dyslipidemia, defined as triglyceride levels above 204 mg/dl 
and HDL-c under 34 mg/dl, benefited from the addition of fenofibrate to statin therapy (HR 
0.73, 95% CI 0.56 – 0.95) [38]. The Pemafibrate to Reduce Cardiovascular OutcoMes by 
Reducing Triglycerides IN patiENts With diabeTes trial (PROMINENT, NCT03071692) is currently 
testing pemafibrate, a new and potent PPAR agonist, in a similar patient population. Most 
pharmacogenetic studies of fibrate response have focused on candidate gene approaches and 
variants in the drug target (PPARA) have been associated with modulation of the effect of 
fenofibrate on triglyceride levels [39]. A first GWAS of fibrate response in the Genetics of Lipid 
Lowering Drugs and Diet Network (GOLDN) and Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) studies identified the gene PBX4 encoding the pre-B-cell leukemia 
homeobox 4 gene as a modulator of the LDL-c response to fenofibrate [40]. 
Niacin 
Niacin is a ligand for the G-protein coupled receptor niacin receptor 1 (also known as 
GPR109A or NIACR1 and encoded by the HCAR2 gene). After binding with niacin, the Gi subunit 
inhibits the adenylate cyclase and the protein kinase A signaling pathway leading to a decrease 
of lipolysis and consequently free fatty acid levels [41]. Niacin increases HDL-c and reduces all 
apoB-containing lipoproteins including Lp(a) which is unaffected by most other lipid-lowering 
drugs (proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors being a notable 
exception) [42-45]. Regardless of its interesting effects on the lipid profile, niacin use is 
hampered by flushing adverse reactions and lack of beneficial effects when added to 
background statin therapy in large clinical trials [46,47]. To date, no large-scale studies have 
evaluated the genetic determinants of niacin response but a small candidate gene 
pharmacogenetic study with 196 participants reported an association between niacin-induced 
flushing and a polymorphism in the liver X receptor α (LXRα) [48]. In a targeted genotyping 
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study, a missense variant in the drug target (HCAR2) was also associated with a decreased 
reduction in Lp(a) by niacin [49]. 
Recent developments in lipid-lowering drugs and a look at the future 
Genomics for drug target identification and validation: PCSK9 inhibitors 
A hallmark of recent developments in cardiovascular drugs is the first successful phase 3 
clinical trial of a PCSK9 antibody. In the Further Cardiovascular Outcomes Research with PCSK9 
Inhibition in Subjects with Elevated Risk (FOURIER) trial, evolocumab added to background 
statin therapy further reduced LDL-c to a median of 30 mg/dl in patients with atherosclerotic 
vascular disease and reduced cardiovascular events with a hazard ratio of 0.85 as compared to 
statin therapy alone [50]. The primary endpoint, a composite of cardiovascular death, 
myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization, 
occurred in 9.8% of the participants in the evolocumab arm compared to 11.3% in the placebo 
arm. Clinically, PCSK9 inhibitors could be used in statin intolerant patients or when LDL-c 
targets are not achieved by statins alone such as for familial hypercholesterolemia patients. 
The development of this new drug is deeply rooted in modern human genetics and is an 
excellent example of genomics-driven drug development. PCSK9 was discovered in 2003 by 
Seidah NH et al. who also underlined its role in cholesterol regulation [51] (reviewed in [52]). 
Two missense gain of function PCSK9 mutations causing autosomal dominant 
hypercholesterolemia were discovered in French families which validated its role in lipid 
disorders [53]. A sequencing study in 128 African American subjects with low plasma LDL-c 
levels identified two nonsense loss of function PCSK9 mutations associated with a 40% 
reduction in plasma LDL-c [54]. A follow-up of the effect of these mutations in 3,363 
participants of the Atherosclerotic Risk in Communities (ARIC) study demonstrated that the 85 
carriers of the loss-of-function mutations had an 88% reduction in risk of coronary heart disease 
when compared to non-carriers [55]. This study also identified rs11591147 (R46L), a loss-of-
function mutation that is more frequent in individuals of European descent (MAF ≈ 3%) with 
concordant yet weaker effects on heart disease risk and LDL-c levels. In a larger meta-analysis 
of 66,698 individuals, individuals with PCSK9 protein variant R46L had reductions of LDL-c levels 
by 0.43 mmol/l (13%) and of ischemic heart disease by 30% compared to non-carriers (95% CI 
for the OR: 0.58 to 0.86) [56]. As the authors noted, the observed reduction in ischemic heart 
disease is larger than expected based on LDL-c reduction alone which could be attributed to 
pleiotropic effects of the mutation, but the lifelong effect of reduced LDL-c levels certainly plays 
a role in this difference. Taken together, these studies have shown how inhibition of PCSK9 
lowers LDL-c levels and the risk for CAD without other obvious side effects, prompting the 
development of therapeutic PCSK9 inhibitors for the treatment of CAD.  
In the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) and 
Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with 
Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY 
LONG TERM) outcome trials of PCSK9 inhibitors, it was noted that neurocognitive events 
occurred more frequently in the treatment arm than the placebo arm (meta-analysis OR=2.81 
[1.32, 5.99]) implying possible adverse effects [57-59]. In contrast, there was no significant 
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deleterious effect of evolocumab on cognition in the EBBINGHAUS substudy of FOURIER [60]. 
Among the other possible consequences of low LDL-c levels achieved by PCSK9 inhibitors is the 
development of type II diabetes, a side effect shared in common with statins [61]. Predicting 
these adverse events can be achieved by looking at the phenotype of individuals carrying PCSK9 
loss-of-function mutations as it was done to predict efficacy. In a Mendelian randomization 
study based on 111,194 Danish individuals, there was no causal association between variants in 
PCSK9 or HMGCR and the risk of Alzheimer’s disease, vascular dementia, all dementia or 
Parkinson’s disease despite increased observational risk for the latter in participants with LDL-c 
levels <1.80 mmol/l when compared to individuals with levels ≥4.0 mmol/l [62]. This finding is 
also supported by prior observational results showing no association between PCSK9 R46L and 
cognitive performance, activities of daily living and non-cardiovascular events in 5,777 
participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) [63]. For 
type II diabetes, the genetic evidence is revealing. Two large instrument variable studies based 
on PCSK9 gene scores showed increases in type II diabetes risk in individuals with genetically 
lowered LDL-c levels [64,65]. This observation is consistent with LDL-c reduction attributable to 
genetic variants in the HMGCR gene [65] and through its pharmacological inhibition by statins 
[61]. Analyses based on all LDL-c-associated variants revealed a negative and significant 
correlation between LDL-c levels and type II diabetes (r=-0.21; P=0.025), but there was 
heterogeneity in the relationship suggesting that not all LDL-c lowering pathways may lead to 
increased type 2 diabetes risk [5]. 
Another interesting approach to predict the consequences of modulating a drug target is 
to test the association between functional variants in the drug target and all the diseases 
recorded in patients’ medical records using a phenome-wide association study (PheWAS). This 
method was first developed by Denny et al. in 2010 and its value is now recognized in the 
context of predicting adverse drug reactions or finding drug repurposing opportunities [66-68]. 
A recent unpublished study tested for the association between the PCSK9 R46L genetic variant 
and 11 selected phenotypes in a targeted analysis as well as with 278 phenotypes in an 
exploratory scan using data from the UK Biobank [69]. A protective effect with ischemic stroke 
(replication OR 0.58 (0.36, 0.89), p=0.02) was detected which is consistent with the known 
atheroprotective effect of PCSK9 inhibitors and the results from recent clinical trials of 
evolocumab [50]. The phenome-wide scan did not show an association between the R46L 
genetic variant and type II diabetes. This may be explained by insufficient statistical power to 
detect such an association or by the phenotyping in the UK Biobank where diagnoses are only 
available for in-patient hospitalizations (and only after 1997-04-01) along with self-reported 
data. 
Human genetics for precision medicine: CETP inhibitors 
The cholesteryl ester transfer protein (CETP) is responsible for the exchange of 
cholesteryl esters and triglycerides between HDL and very low-density lipoproteins and LDL 
[70].  
Interest for CETP as a drug target stems from human genetic evidence that some CETP 
mutations increase HDL-c while slightly lowering LDL-c and apolipoprotein B leading to an 
atheroprotective lipid profile [71]. Multiple polymorphisms affecting plasma CETP 
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concentrations or CETP activity have been discovered. Among the most widely studied are 
TaqIB (rs708272) located in intron 1 and -629C>A (rs1800775 also identified in HGVS as 
NM_000078.2:c.-656C>A and NM_001286085.1:c.-656C>A) located in the promoter. These two 
variants are in high linkage disequilibrium (LD) (R2=0.77 in 1000 genomes Europeans) and 
haplotype and statistical fine-mapping suggested that the association of TaqIB is likely 
mediated by the functional -629C>A variant [72]. Other CETP promoter variants explain 
additional variance in CETP concentration and HDL-c levels which suggests a spectrum of 
regulatory alleles. When considered alone, the -629C>A variant had the strongest association 
with CETP concentration explaining 7.9% of the variance and 4.6% of the variance in HDL-c 
levels. Functional studies have also shown that the ‘A’ allele reduces CETP levels potentially 
because of increased affinity with the Sp1 and Sp3 transcription factors that are repressors of 
promoter activity [73]. In a meta-analysis of CETP phenotypes and coronary disease, both TaqIB 
and -629C>A had a significant effect on CETP activity, HDL-c levels and apolipoprotein A-I 
concentrations. The HDL-c increasing allele for these variants also had a protective effect 
against coronary disease (-629C>A OR=0.95 (0.91, 1.00)) [74]. These results are consistent with 
the latest results from the Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia 
projects presenting results from an exome-wide association meta-analysis of 42,335 coronary 
artery disease cases and 78,240 controls genotyped on the exome array. In this study, CETP -
629C>A was the lead SNP at the locus and the OR for the HDL-c increasing allele was 0.96 (0.94, 
0.97) [75]. The protective allele was also associated with decreased LDL-c and triglyceride levels 
suggesting pleiotropic effects of CETP modulation. 
Recently, targeted CETP sequencing in 58,469 participants identified protein-truncating 
variants (PTV). PTVs are more likely to yield proteins with lower activity or reduced expression 
through nonsense-mediated decay and are more likely to have effects similar to pharmacologic 
antagonists. In this study, individuals carrying CETP PTV had increased HDL-c levels (by 22.6 
mg/dl), lower LDL-c levels (by 12.2 mg/dl) and lower triglyceride levels (by 6.3%) as well as a 
reduced risk for coronary heart disease (OR=0.70, 95% CI 0.54 to 0.90) as compared to non-
carrier individuals [76]. This effect is far greater than the one observed with common promoter 
variants and the greater reduction in risk for CAD is concordant with a dose-response effect of 
CETP modulation. The authors also highlight that the effect of CETP PTV is concordant with the 
lifelong benefits of LDL-c reduction as observed in carriers of PCSK9, APOB or NPC1L1 PTV. 
Despite the genetic evidence supporting CETP as a useful drug target, previous trials of 
CETP inhibitors have failed due to safety concerns (for torcetrapib) or lack of efficacy alone 
(evacetrapib) [77]. Nonetheless, in 2017 the Randomized EValuation of the Effects of 
Anacetrapib Through Lipid-modification (REVEAL) trial compared anacetrapib to placebo in 
30,449 atherosclerotic vascular disease patients receiving atorvastatin, and showed a 
statistically significant reduction in the primary composite outcome of coronary death, 
myocardial infarction or coronary revascularization in the anacetrapib group [78]. The observed 
rate ratio between both arms of 0.91 (95% CI, 0.85 – 0.97) represents a relatively modest risk 
reduction given the background statin therapy. The exact mechanism behind the observed 
protective effects is still debated, but the results from this clinical trial are in line with the 
observations from genetic variants reducing CETP activity and provides a first validation of the 
drug target from a randomized controlled trial. 
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After the dal-OUTCOMES trial of dalcetrapib in acute coronary syndrome patients failed 
to show efficacy in reducing cardiovascular event rates globally, our group performed a 
pharmacogenomic GWAS to identify genetic modulators of dalcetrapib response. This scan 
revealed an association at the ADCY9 locus where homozygotes for the ‘A’ allele at the lead 
SNP, rs1967309, which represents approximately 17% of Europeans, had a 39% (HR=0.61, 95% 
CI, 0.41 – 0.92) relative risk reduction for a composite of cardiovascular events as compared to 
placebo [79]. This risk reduction was also supported by results from an imaging study, dal-
PLAQUE-2, where several variants in the locus and in linkage disequilibrium with rs1967309 
were associated with a reduction of intima-media thickness in individuals with the protective 
alleles treated with dalcetrapib, but not with a placebo. Individuals with the rs1967309 “GG” 
genotype, representing approximately 35% of Europeans, had a 27% increase in risk of 
cardiovascular events when treated with dalcetrapib compared to placebo (HR: 1.27, 95% CI, 
1.02 – 1.58) and heterozygotes had a neutral effect. In “G” allele carriers, there was also an 
increase in C-reactive protein in individuals treated with dalcetrapib but this systemic 
inflammation marker was unchanged in “AA” individuals. The capacity of the participant’s 
serum to efflux cholesterol from J774 macrophages was also measured. Cholesterol efflux is an 
important function of HDL where peripheral cholesterol is ultimately transported back to the 
liver through the reverse cholesterol transport pathway, potentially reducing atherosclerosis 
and the risk for CAD independently from HDL-c levels [80,81]. Individuals with the “AA” 
genotype treated with dalcetrapib had a 22.3% increase in cholesterol efflux from baseline vs 
3.5% in the placebo arm, in contrast to patients with the “GG” genotype who had no benefit of 
dalcetrapib [82]. Interestingly, rs1967309 genotypes were also associated with changes in 
weight in response to dalcetrapib treatment but not with placebo. The underlying mechanisms 
responsible for the interaction between ADCY9 and CETP have not yet been entirely elucidated. 
ADCY9 encodes adenylate cyclase type 9, an enzyme producing the ubiquitous second 
messenger cyclic AMP. Studies in genetically-modified mice have shown that the removal of 
ADCY9 expression results in a large reduction in atherosclerosis, but only in the absence of CETP 
(results pending publication). In a GWAS meta-analysis, an ADCY9 SNP known to influence gene 
expression has been linked with class I obesity in over 39,000 cases [83]. Another recent report 
also identified familial mutations in another adenylate cyclase isoform encoded by ADCY3 
causing monogenic obesity [84]. 
Currently, the dal-GenE trial (NCT02525939) is testing dalcetrapib compared to placebo 
in acute coronary syndrome patients on the reduction of cardiovascular events in a targeted 
genetic population defined by the rs1967309 “AA” genotype. This phase III trial could be the 
first to lead to the approval of a cardiovascular drug specifically in individuals with a genetically-
determined responder profile and co-developed with a companion diagnostic test. A positive 
trial would go a long way to validate the hypothesis-free approach used by our group to identify 
predictive biomarkers of drug efficacy, representing an important milestone toward the 
personalization of novel therapies [85]. 
Drugs in the pipeline 
Multiple novel small molecules for lipid-lowering therapies are currently in the drug 
development pipeline. The review by Gryn and Hegele provides a very interesting overview of 
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developments in orally administered lipid-lowering therapies [86]. Here, we will focus primarily 
on the development of novel drugs that are supported by strong human genetics evidence. 
Triglyceride levels are consistently associated with increased CAD in prospective studies 
[87]. Mendelian randomization studies where genetic variants are used to compare the effect 
of genetically-determined triglyceride levels on CAD support the causality of the observed 
association, suggesting that interventions aimed at lowering triglyceride levels could be used to 
reduce the risk for CAD [88]. The effect size of variants associated with triglyceride levels also 
correlates with that on CAD, which supports the hypothesis of causality (Pearson’s R=0.46, 
p=0.02) [6]. 
In a sequencing study of Amish participants of the Heredity and Phenotype Intervention 
(HAPI) Heart Study, a rare nonsense mutation in the gene encoding apolipoprotein CIII (APOC3) 
was identified [89]. Apolipoprotein CIII is an important modulator of triglyceride levels. It 
inhibits lipoprotein lipase (LPL) which catalyzes the hydrolysis of triglyceride-rich lipoproteins 
and modulates the hepatic uptake of their remnants [90]. APOC3 is also thought to have other 
pleiotropic effects including the modulation of cholesterol efflux [91,92]. In heterozygous 
APOC3 mutation carriers, the median fasting triglyceride level was 31 mg/dl vs 57 mg/dl for 
non-carriers. Individuals carrying the mutation also had significantly higher HDL-c and lower 
levels of LDL-c, VLDL-c, IDL-c and remnant lipoprotein cholesterol. The development of CAD was 
not evaluated in these individuals, but the heterozygotes did have less detectable coronary 
artery calcification, a marker of subclinical atherosclerosis [89]. Subsequent sequencing studies 
have confirmed this nonsense mutation (R19X) and identified three other loss-of-function 
APOC3 mutations associated with reduced triglyceride levels (R19X, IVS2+1G>A, A43T and 
IVS3+1G>T) [93,94]. Participants carrying these mutations were protected against ischemic 
vascular disease, emphasizing the benefit of lifelong low nonfasting triglyceride levels and 
established APOC3 as an interesting drug target. Furthermore, the authors found no association 
between the APOC3 mutations and inflammation, dementia, cancer or total mortality 
supporting the lack of serious on-target adverse effects [94]. An antisense inhibitor of APOC3, 
volanesorsen (ISIS 304801), was proven to reduce triglyceride levels and is currently being 
evaluated in phase III trials. The successful development of this drug would, as for PCSK9 
inhibitors, be an example of genomics-driven drug development. 
Another therapeutic target modulating triglyceride levels is angiopoietin-like 3 encoded 
by the ANGPTL3 gene which inhibits the lipoprotein lipase (LPL) and endothelial lipase (LIPG) 
responsible for the hydrolysis of circulating triglycerides and HDL phospholipids, respectively 
[95]. This gene was first associated with lipid metabolism in mice where a 4 bp insertion leads 
to a frameshift and a premature termination of the protein along with decreased triglyceride 
levels [96]. In a 2008 GWAS, a common ANGPTL3 variant rs1748195 (MAF=30%) was associated 
with a 7.12 mg/dl reduction in triglyceride levels [10,11]. In a later GWAS with increased sample 
size, statistically significant effects of ANGPTL3 variants on total cholesterol, LDL-c, triglycerides 
but not HDL-c were detected [6]. Similar results were obtained in a large-scale study of the 
deCODE project where the ANGPTL3 variants were associated with triglyceride levels and non-
HDL cholesterol despite having no effect on HDL-c [97]. To date, the association between 
common ANGPTL3 polymorphisms and CAD has been conflicting. Two large studies found no 
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association between common ANGPTL3 variants and CAD in CARDIoGRAM (22,233 cases) and 
deCODE (33,090 cases) and a meta-analysis of two case-control studies, three cross-sectional 
and seven prospective studies including 5,794 CAD cases found a counterintuitive association 
where the total cholesterol, LDL-c and triglyceride lowering allele increased risk for CAD [97-
99]. These results could be attributable to the milder effect of common polymorphisms as 
recent large-scale studies of rare loss-of-function ANGPTL3 variants have consistently shown a 
risk reduction for CAD of around 40% [100,101]. To date, both evinacumab, a monoclonal 
antibody against ANGPTL3 and IONIS-ANGPTL3-LRx, an antisense targeting ANGPTL3 mRNA, 
have shown promising results in phase II trials and a phase III trial is underway (NCT03399786) 
[101,102].  
ANGPTL4 is another interesting angiopoietin-like protein that also inhibits LPL. The 
strongest association signal with common variants in ANGPTL4 was originally found with HDL-c 
levels, but associations with other lipid fractions including triglycerides were later shown [6,97]. 
Common triglyceride-lowering variants in ANGPTL4 are protective against CAD in case-control 
studies [97]. As for ANGPTL3, exome sequencing and genotyping studies found a mutation, 
ANGPTL4 p.E40K, which reduces triglyceride levels and risk of CAD [103,104]. This variant was 
also found to be protective for type 2 diabetes and to have no effect on fatty liver, a frequent 
consequence of hypobetalipoproteinemia [5,105]. Mutations in LPL have also been found to 
increase triglyceride levels and the risk for CAD [106]. Using monoclonal ANGPTL4 antibodies in 
mice and monkeys resulted in lowered triglyceride levels, but also resulted in the accumulation 
of lipids in mesenteric lymph nodes, possibly decreasing the interest in pursuing ANGPTL4 as a 
drug target in humans [103]. 
Finally, lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein similar to LDL with an added 
apolipoprotein(a) covalently bound to the apolipoprotein B100 molecule [107]. Lp(a) has been 
linked to increased risk for CAD in epidemiological studies and in Mendelian randomization 
analyses [108,109]. In addition to its atherogenic effect, the similarity between 
apolipoprotein(a) and plasminogen interferes with fibrinolysis leading to a prothrombotic 
effect. In addition, Lp(a) carries proinflammatory oxidized phospholipids [110,111]. Two genetic 
variants, rs10455872 and rs3798220, explain 36% of the total variance in Lp(a) levels and 
carriers of two or more variant alleles have a 2.57 (95% CI, 1.80 – 3.67) odds ratio for coronary 
disease as compared to non-carriers [112]. Niacin and PCSK9 inhibitors are the only drugs 
currently known to significantly reduce Lp(a) levels. Recently, phase II trials of LPA antisense 
oligonucleotides have demonstrated reductions in Lp(a) levels of 67-72% [113]. Although the 
results are promising, whether this reduction in Lp(a) levels will translate into improvements of 
cardiovascular outcomes will need to be assessed in larger phase III trials. 
This section provided multiple examples of drug targets discovered or supported by 
human genetic studies. The ongoing development of the next generation of lipid-regulating 
drugs has been heavily influenced by the observable consequences of mutations in human 
populations. This genomics-driven approach, catalyzed by the emergence of monoclonal 
antibodies and antisense drugs, could improve the performance of the drug discovery pipeline 
for cardiovascular diseases and reduce the current high attrition rates. 
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The polygenic shift in precision medicine 
The main goal of pharmacogenetics has long been to identify predictive biomarkers associated 
with drug response. Such predictive genetic variants can then serve to optimize treatment by 
allowing to select the appropriate medication or adjust dosage. The Clinical Pharmacogenetics 
Implementation Consortium (CPIP) regularly publishes clinical guidelines based on the 
pharmacogenetics literature to guide clinical implementation [114]. Guidelines for many drugs 
including clopidogrel, warfarin and simvastatin have been published, but there are still only few 
real-world clinical cases of implementation. In these pharmacogenetic approaches, variants are 
used as predictive biomarkers of the treatment safety or efficacy [115]. Recently, the possibility 
of using prognostic pharmacogenetic markers has emerged. The goal of prognostic biomarkers 
is not to directly predict drug response but rather to predict disease incidence and severity 
which in turn can be used to guide pharmacological treatment. For example, in a recent analysis 
of primary and secondary prevention statin trials, it has been shown that individuals in the high 
genetic risk group for CAD derived increased relative and absolute benefit from statins [116]. 
Using a genetic risk score based on 27 SNPs confidently associated with CAD, the authors have 
observed a relative risk reduction of cardiovascular events in the primary prevention setting of 
34% with statin therapy compared to placebo for individuals in the low genetic risk group, 32% 
in the intermediate group and 50% in the high genetic risk group. These differences are 
potentially clinically relevant as the number of individuals needed to treat with statins to 
prevent one cardiovascular event in 10 years greatly differed from 66 in the low group to 25 in 
the high-risk group in the Justification for the Use of Statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER) trial. Another group observed a similar risk reduction in 
cardiovascular events of 44% with pravastatin versus placebo in the high genetic risk group 
based on the West of Scotland Coronary Prevention Study (WOSCOPS) statin primary 
prevention trial [117]. In this study, participants in the high genetic risk had also increased 
coronary artery calcification and a higher burden of carotid plaque. The findings from these 
studies could tilt the controversial risk-benefit balance of statin pharmacotherapy in the 
primary prevention setting for patients at high genetic risk of CAD [118]. 
As GWAS of common diseases become larger, it becomes possible to derive meaningful 
polygenic measures that account for a large proportion of the total genetic risk of disease. 
Compounded with methodological improvements in genomic prediction models, we expect 
these tools to help identify high benefit subpopulations that can streamline drug development 
and help guide clinical decisions. In a recent study, individuals with a high polygenic risk score 
for CAD were shown to have a cardiovascular risk profile similar to heterozygous familial 
hypercholesterolemia mutation carriers [119,120]. For the same level of risk, 1 in every 53 
individuals was at high polygenic risk compared to 1 in 256 individuals for the familial genetic 
variants. This recent evidence reinforces the relevance of polygenic measures of risk as 
prognostic biomarkers and marks a shift in complex trait genomics away from single-variant 




In this review, we have illustrated the different ways by which genomic approaches can be used 
to inform on the use and development of lipid-regulating medication. A useful drug 
development model has emerged which builds on the single causal variant discoveries from 
rare familial diseases followed by the rapid development of antisense oligonucleotides or 
monoclonal antibodies. These innovations are in line with the initial expectations of the Human 
Genome Project and can be considered a success of genomic medicine.  
At the population level, the importance of polygenic risk scores is becoming evident. Thanks to 
GWAS of impressive sizes, it is now possible to build strong genomic predictors of disease 
incidence that also predict an individual’s response to environmental factors or drugs. Because 
these genetic scores are constant throughout life, they offer interesting practical and economic 
benefits which could change the way preventive cardiovascular medicine is done. Nonetheless, 
additional challenges will need to be addressed for a true personalized medicine to emerge. For 
instance, polygenic scores have heterogeneous performance across ethnicity and sex and are 
strongly biased towards European males who are overrepresented in the GWAS from which 
polygenic scores are typically based. We expect further methodological developments to 
partially account for these biases, but increasing diversity in large genetic trials will be 
paramount to truly improve the clinical relevance of these promising novel methods.  
Executive summary 
Pharmacogenetics of current blood lipid drugs  
• Statins are the most widely studied blood lipid drugs in pharmacogenetics. Variants in 
different transporters, metabolizing enzymes and lipid metabolism genes are associated 
with adverse effects or statin response. 
• Other important drugs are ezetimibe, fibrates and niacin.  
PCSK9 inhibitors as an example of genomics-driven drug development 
• Both gain-of-function and loss-of-function PCSK9 mutations have been identified in 
families and at the population scale. Loss-of-function of PCSK9 is protective for coronary 
artery disease. 
• Monoclonal antibodies against PCSK9 have now been demonstrated to reduce 
cardiovascular events in a phase III trial. 
CETP as a drug target is supported by human genetics evidence and common variants in 
ADCY9 determine dalcetrapib efficacy 
• Common functional variants and rare protein truncating variants in CETP are associated 
with increased HDL-c and lower risk for coronary artery disease. 
• The recent phase III REVEAL trial demonstrated a reduction in coronary events with 
anacetrapib, a CETP inhibitor.  
• A common ADCY9 variant determines dalcetrapib efficacy and is currently being used as 
an entry criterion in the dal-GenE phase III trial. 
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Novel blood-lipid drugs 
• Many recent blood-lipid drugs are antisense or monoclonal antibodies for genes 
implicated in lipid regulation such as APOC3 and ANGPTL3. 
• Lipoprotein(a) is another important risk factor supported by recent genetics evidence. 
Antisense oligonucleotides are being developed to reduce Lp(a) levels further than 
current drugs such as PCSK9 inhibitors and niacin. 
The polygenic shift in precision medicine 
• Identifying variants that modulate drug response is important for the development of 
predictive biomarkers of drug efficacy.  
• New approaches focus on the use of prognostic biomarkers of disease risk such as 
polygenic risk scores to identify patients with high potential benefit from 
pharmacological treatment. 
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